AR054529A1 - Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 - Google Patents
Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6Info
- Publication number
- AR054529A1 AR054529A1 ARP060102857A ARP060102857A AR054529A1 AR 054529 A1 AR054529 A1 AR 054529A1 AR P060102857 A ARP060102857 A AR P060102857A AR P060102857 A ARP060102857 A AR P060102857A AR 054529 A1 AR054529 A1 AR 054529A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- haloalkyl
- halogen
- cor11
- so2r11
- Prior art date
Links
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical class N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 21
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 3
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006642 (C1-C6) cyanoalkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 101100203602 Hypocrea jecorina (strain QM6a) sor7 gene Proteins 0.000 abstract 1
- -1 N (R8) SO2R7 Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 238000013160 medical therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Procesos para su preparacion, intermediarios usados en su preparacion, composiciones farmacéuticas que contienen dichos compuestos y al uso de dichos compuestos en la terapia médica. Reivindicacion 1: Un compuesto de formula (1) donde: Q es arilC6- 10alquiloC0-6, heteroarilC5-11alquiloC0-6, cicloalquilC3-7alquiloC0-6, heterocicloalquilC3-7alquiloC0-6 o alquiloC1-10; R1 es H, hidroxilo, halogeno, alquiloC1-10, alqueniloC2-10, alquiniloC2-10, alcoxiC1-10, N(R10) 2, arilC6-10alquiloC0-6, heteroarilC5-6alquiloC0-6, haloalquiloC1-6, haloalquilC1-6O, R8OalquiloC0-6, CN, SR7, R7SO2alquiloC0-6, SO2R7, R7CON(R8)alquiloC0-6, NR8SO2R7, COR7, COOR8, OSO2R8, (R8)2NCOalquiloC0-6, SO2N(R8)2, N(R8)CON(R8)2, NO2, cicloalquiloC3-6, heterocicloalquiloC3-6 u oxo; n es 0, 1, 2, 3, 4, o 5; B es O, N(R6)2, o B es NR6 dentro de un heteroariloC5-11 donde R6 forma un anillo con Q; X es O, CH2, CO, S, SO, SO2 o NR12; R2 es H, hidroxilo, halogeno, alquiloC1-10, alqueniloC2-10, alquiniloC2-10, alcoxiC1-10, N(R10)2, arilC6-10alquiloC0-6, heteroarilC5-6alquiloC0-6, haloalquiloC1-6, haloalquilC1-6O, R7OalquiloC0-6, CN, SR7, SO2R8, SOR7, N(R8)COR7, N(R8) SO2R7, COR7, COOR7, OSO2R7, CON(R8)2 o SO2N(R8)2; R3 es H, alquiloC1-10, alqueniloC2-10, alquiniloC2-10, arilC6-10alquiloC0-6, heteroarilC5-6alquiloC0-6, haloalquiloC1-6 o R7OalquiloC1-6; R4 es H, alquiloC1-5, haloalquiloC1-5, alcoxiC1-5 o haloalcoxiC1-5 y puede estar sustituido con 1 o varios grupos seleccionados independientemente de halogeno, hidroxilo, ciano, alquiloC1-3 y alcoxiC1-3; o R3 y R4 juntos forman un heterocicloalquiloC3-7, el cual puede estar sustituido con 1 o varios grupos seleccionados independientemente de H, halogeno, alquiloC1-6, haloalquiloC1-6, COR11, SO2R11, OR11, ciano, oxo y SO2N(R10)2; R5 es H, alquiloC1-6, alcoxiC1-6, haloalcoxiC1-6 o haloalquiloC1-6; o R4 y R5 juntos forman un heterocicloalquiloC3-7 o un cicloalquiloC3-7, el cual puede estar sustituido con 1 o varios grupos seleccionados independientemente de H, halogeno, alquiloC1-6, haloalquiloC1-6, COR11, SO2R11, OR11, ciano, oxo y SO2N(R10)2; R6 es H, alquiloC1-6, cicloalquilC3-6alquiloC0-6, R7OalquiloC1-6, haloalquiloC1-6, cianoalquiloC1-6, (R10)2NCOalquiloC0-6 o R11SO2alquiloC1-6; R7 es alquiloC1-6, arilC6-10alquiloC0-6, heteroarilC5-6alquiloC0-6, cicloalquilC3-7alquiloC0-6 o haloalquiloC1-6; R8 es H, alquiloC1-6, haloalquiloC1-6, cicloalquilC3-7alquiloC0-6, arilC6-10alquiloC0-6 o heteroarilC5-6alquilC0-6; o R7 y R8 juntos forman un heteroariloC5-6 o un heterocicloalquiloC3-7; donde cualquier arilo y heteroarilo bajo R1, R3, R7 y R8 puede estar sustituido con 1 o varios grupos seleccionados independientemente de H, halogeno, hidroxilo, haloalquiloC1-6, CN, OR10, alquiloC1-6, oxo, SR10, CON(R10)2, N(R10)COR11, SO2R11, SOR11, N(R10)2 y COR11; R9 es H, hidroxilo, halogeno, alquiloC1-6, alcoxiC1-6alquiloC0-3, haloalquiloC1-6, COR11, CON(R10)2, N(R10)COR11, SR10 SOR11, CN o SO2R11; R10 es H, alquiloC1-6 o haloalquiloC1-6; R11 es alquiloC1-6 o haloalquiloC1-6; o R10 y R11 juntos forman un heterocicloalquiloC3-7, el cual puede estar sustituido con uno o varios grupos seleccionados independientemente de H, halogeno, hidroxilo, alquiloC1-3, alcoxiC1-3 y ciano; y R12 es H, alquiloC1-6, haloalquiloC1-6, COR11 o SO2R11; o sus sales, solvatos o sales solvatadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501579 | 2005-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054529A1 true AR054529A1 (es) | 2007-06-27 |
Family
ID=37604726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102857A AR054529A1 (es) | 2005-07-05 | 2006-07-03 | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100105657A1 (es) |
| EP (1) | EP1910321A4 (es) |
| JP (1) | JP2009501705A (es) |
| CN (1) | CN101258135A (es) |
| AR (1) | AR054529A1 (es) |
| WO (1) | WO2007004959A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008007661A1 (en) * | 2006-07-11 | 2008-01-17 | Takeda Pharmaceutical Company Limited | Tricyclic heterocyclic compound and use thereof |
| CA2659956C (en) * | 2006-08-04 | 2016-01-05 | Lewis C. Cantley | Inhibitors of pyruvate kinase and methods of treating disease |
| WO2008108445A1 (ja) * | 2007-03-07 | 2008-09-12 | Takeda Pharmaceutical Company Limited | ベンゾオキサゼピン誘導体およびその用途 |
| WO2008116833A1 (en) | 2007-03-23 | 2008-10-02 | Abbott Gmbh & Co. Kg | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| EP2116547A1 (en) * | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands |
| EP2116546A1 (en) | 2008-05-09 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| PL2427441T3 (pl) | 2009-05-04 | 2017-06-30 | Agios Pharmaceuticals, Inc. | Aktywatory PKM2 do stosowania w leczeniu raka |
| JP5764555B2 (ja) | 2009-06-29 | 2015-08-19 | アジオス ファーマシューティカルズ， インコーポレイテッド | 治療組成物および関連する使用方法 |
| NZ622505A (en) | 2009-06-29 | 2015-12-24 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| RU2015140748A (ru) * | 2010-05-21 | 2018-12-26 | Эббви Инк. | Модуляторы 5-нт рецепторов и способы их применения |
| JP5837091B2 (ja) | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２（ｐｋｍ２）調節剤としての新規ｎ−（４−（アゼチジン−１−カルボニル）フェニル）−（ヘテロ−）アリールスルホンアミド誘導体 |
| WO2012088314A1 (en) | 2010-12-21 | 2012-06-28 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| PT2704721T (pt) | 2011-05-03 | 2018-06-14 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| RS64777B1 (sr) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals Inc | Postupci upotrebe aktivatora piruvat kinaze |
| KR102172595B1 (ko) * | 2018-12-19 | 2020-11-02 | 인하대학교 산학협력단 | 벤조옥사제핀 유도체 화합물을 포함하는 비만 예방 또는 치료용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW458978B (en) * | 1995-11-07 | 2001-10-11 | Astra Ab | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase |
| SE9701681D0 (sv) * | 1997-05-05 | 1997-05-05 | Astra Ab | New compounds |
| CA2347095A1 (en) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Nitrogen-containing condensed heterocyclic derivatives, their production and agent |
| JP2000186088A (ja) * | 1998-10-16 | 2000-07-04 | Takeda Chem Ind Ltd | 含窒素縮合複素環誘導体、その製造法および用途 |
| GB9926302D0 (en) * | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| ATE340795T1 (de) * | 2001-01-30 | 2006-10-15 | Lilly Co Eli | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten |
| EP1450806B1 (en) * | 2001-11-09 | 2009-04-29 | Biovitrum AB (publ) | Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake |
| TW200306843A (en) * | 2002-02-13 | 2003-12-01 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-07-03 AR ARP060102857A patent/AR054529A1/es not_active Application Discontinuation
- 2006-07-03 JP JP2008520212A patent/JP2009501705A/ja active Pending
- 2006-07-03 CN CNA2006800324555A patent/CN101258135A/zh active Pending
- 2006-07-03 EP EP06758020A patent/EP1910321A4/en not_active Withdrawn
- 2006-07-03 WO PCT/SE2006/000827 patent/WO2007004959A1/en not_active Ceased
- 2006-07-03 US US11/993,377 patent/US20100105657A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007004959A1 (en) | 2007-01-11 |
| EP1910321A1 (en) | 2008-04-16 |
| EP1910321A4 (en) | 2010-09-01 |
| US20100105657A1 (en) | 2010-04-29 |
| CN101258135A (zh) | 2008-09-03 |
| JP2009501705A (ja) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
| ES2528451T3 (es) | Inhibidores de esfingosina cinasa | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| AR060267A1 (es) | Tiazolil- dihidro -ciclopentapirazoles | |
| AR072657A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| CO5650257A2 (es) | Derivados de pirazol [1,5-a]pirimidina | |
| AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| AR069765A1 (es) | 4-(4-ciano) 2- tioaril) dihidropirimidonas y su uso | |
| AR044342A1 (es) | Derivados de bencimidazol | |
| AR045979A1 (es) | Amidas heterociclicas | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR054363A1 (es) | Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6 | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| ECSP088194A (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |